ARTICLE | Company News
Mustang licenses immunodeficiency gene therapy from St. Jude
August 13, 2018 8:50 PM UTC
Mustang Bio Inc. (NASDAQ:MBIO) gained exclusive, worldwide rights to develop and commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital.
St. Jude will receive an upfront payment and is eligible for milestones and royalties. Financial terms are undisclosed...
BCIQ Target Profiles